China Pharma Holdings, Inc. (CPHI)
| Market Cap | 35.53M |
| Revenue (ttm) | 10.98M |
| Net Income (ttm) | -20.40M |
| Shares Out | 43.58M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $0.780 |
| Previous Close | $0.774 |
| Change ($) | 0.006 |
| Change (%) | 0.78% |
| Day's Open | 0.761 |
| Day's Range | 0.708 - 0.789 |
| Day's Volume | 451,364 |
| 52-Week Range | 0.320 - 1.310 |
Face mask play China Pharma Holdings is trending higher today, and investors are noticing. Here is what you should know about CPHI stock.
China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript
China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript
China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript
China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript
About CPHI
China Pharma Holdings develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brai... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | |
| CEO Zhilin Li | Employees 228 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol CPHI |
Financial Performance
In 2019, CPHI's revenue was $10.92 million, a decrease of -11.41% compared to the previous year's $12.33 million. Losses were -$20.70 million, 92.6% more than in 2018.